Table A1.
Clinical Outcome Analysis by Treatment Arm (No-GO v GO) for Lower (Q1 to Q2) Versus Higher (Q2 to Q4) CD33 Expression
| All Patients (%) | ||||||
|---|---|---|---|---|---|---|
| CD33 Q1-Q2 (n = 413) | P | CD33 Q3-Q4 (n = 412) | P | |||
| No-GO (n = 214) | GO (n = 199) | No-GO (n = 197) | GO (n = 215) | |||
| 5-year OS from study entry, mean ± SD | 68 ± 7 | 71 ± 7 | .706 | 58 ± 7 | 62 ± 7 | .350 |
| 5-year EFS from study entry, mean ± SD | 51 ± 7 | 57 ± 7 | .230 | 40 ± 7 | 49 ± 7 | .086 |
| No-GO (n = 157) | GO (n = 147) | No-GO (n = 124) | GO (n = 164) | |||
| 5-year DFS from end of induction I, mean ± SD | 58 ± 8 | 65 ± 8 | .281 | 45 ± 9 | 56 ± 8 | .035 |
| 5-year RR from end of induction I, mean ± SD | 40 ± 8 | 28 ± 8 | .036 | 50 ± 9 | 37 ± 8 | .016 |
Abbreviations: DFS, disease-free survival; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival; Q, quartile; RR, relapse risk.